Core Viewpoint - Chengyi Pharmaceutical (603811.SH) has received approval from the National Medical Products Administration for the registration certificate of Eicosapentaenoic Acid Ethyl Ester Soft Capsules, aimed at reducing triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) [1] Group 1 - The product is intended for use in conjunction with dietary control to lower triglyceride levels in patients with severe hypertriglyceridemia [1] - It is also indicated for adult patients with confirmed cardiovascular disease or diabetes with two or more other cardiovascular risk factors, combined with hypertriglyceridemia (≥150 mg/dL), to reduce the risk of cardiovascular events such as myocardial infarction, stroke, coronary artery revascularization, and unstable angina requiring hospitalization [1] - The impact of this product on the risk of pancreatitis in patients with severe hypertriglyceridemia has not yet been evaluated [1]

Summary of Key Points Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. has successfully completed its share repurchase plan, utilizing a total of approximately 76.4 million yuan to buy back 9,618,796 shares, which represents 2.94% of its total share capital. The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3]. Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on October 1, 2024, with a planned implementation period from September 30, 2024, to September 29, 2025 [1]. - The expected repurchase amount ranges from 50 million yuan to 100 million yuan [1]. - The repurchase was conducted through centralized bidding, with the actual repurchase price ranging from 7.25 yuan to 8.36 yuan per share, and an average price of 7.94 yuan per share [3]. Group 2: Implementation Status - As of the announcement date, the company has reached the lower limit of the repurchase amount, completing the share repurchase plan [3]. - The total amount paid for the repurchased shares was 76,397,831.64 yuan, excluding transaction fees [3]. - The company used its own funds and a special bank loan for the repurchase, ensuring that the operation would not significantly impact its business, finances, or future development [3]. Group 3: Shareholder Transactions - There were no stock trading activities by the actual controller, major shareholders, directors, supervisors, or senior management from the date of the initial disclosure of the repurchase plan until the announcement date [3]. Group 4: Future Plans for Repurchased Shares - The repurchased shares will be used for employee stock ownership plans, as approved in a board meeting held on August 11, 2025 [4][5].

Overview - Zhejiang Chengyi Pharmaceutical Co., Ltd. has received the drug registration certificate for Eicosapentaenoic Acid Ethyl Ester Soft Capsules from the National Medical Products Administration [1][2] Drug Information - The drug is approved for use in lowering triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) and is indicated for use in conjunction with statins for patients with cardiovascular disease or diabetes with multiple cardiovascular risk factors [1] - The drug has been classified as a Class 4 chemical drug and is considered to have passed the consistency evaluation for generic drugs [2] Company Impact - The company has invested a total of 15.603 million yuan in the research and development of Eicosapentaenoic Acid Ethyl Ester Soft Capsules [2]

诚意药业公告，近日收到国家药监局核准签发的二十碳五烯酸乙酯软胶囊《药品注册证书》。该药品在 控制饮食的基础上，用于降低重度高甘油三酯血症（≥500mg/dL）成年患者的甘油三酯（TG）水平。 与他汀类药物联合使用，用于确诊心血管疾病或糖尿病伴≥2种其他心血管疾病危险因素，合并高甘油 三酯血症（≥150mg/dL）的成年患者，以降低心血管事件风险。公司二十碳五烯酸乙酯软胶囊的研发投 入共计1560.3万元。 ...

二、回购实施情况 （一）2024 年 10 月 8 日，公司通过回购专用证券账户以集中竞价交易方式 首次实施了股份回购，并披露了首次回购股份情况，具体内容详见公司于 2024 年 10 月 9 日在上海证券交易所网站（www.sse.com.cn）披露的《浙江诚意药业股份 有限公司关于以集中竞价方式首次回购公司股份的公告》（公告编号：2024-033）。 证券代码：603811 证券简称：诚意药业 公告编号：2025-050 浙江诚意药业股份有限公司 关于回购完成暨回购实施结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/1 | | --- | --- | | 回购方案实施期限 | 2024.9.30~2025.9.29 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 961.8 ...

证券代码： 603811 证券简称：诚意药业 公告编号：2025-049 浙江诚意药业股份有限公司 关于二十碳五烯酸乙酯软胶囊获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，浙江诚意药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的二十碳五烯酸乙酯软胶囊（以下 简称"本品"）《药品注册证书》（证书编号：2025S02619、2025S02620），现 将具体情况公告如下： 二、药品的基本情况 1、药品名称：二十碳五烯酸乙酯软胶囊 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 1 2、剂型：胶囊剂 3、规格：0.5g；1.0g 4、证书编号：2025S02619；2025S02620 5、药品注册标准编号：YBH20232025 6、申请事项：药品注册(境内生产) ...

Core Viewpoint - Chengyi Pharmaceutical (603811) reported strong financial performance for the first half of 2025, with significant increases in revenue and net profit compared to the previous year [1][3]. Financial Performance - Total revenue reached 417 million yuan, a year-on-year increase of 17.11% [1] - Net profit attributable to shareholders was 112 million yuan, up 47.03% year-on-year [1] - In Q2 alone, revenue was 231 million yuan, reflecting a 13.98% increase year-on-year, while net profit for the quarter was 66.63 million yuan, up 52.19% [1] - Gross margin improved slightly to 69.78%, with a net margin of 27.34%, an increase of 27.15% year-on-year [1] Cost and Expense Management - Total selling, administrative, and financial expenses amounted to 149 million yuan, accounting for 35.7% of revenue, a decrease of 17.52% year-on-year [1] - Research and development expenses decreased by 14.58%, attributed to lower employee compensation and material costs [3] Cash Flow and Assets - Operating cash flow per share increased significantly by 113.74% to 0.43 yuan [1] - Cash and cash equivalents rose to 62.67 million yuan, a 12.13% increase [1] - Accounts receivable decreased by 32.82% to 43.67 million yuan, indicating improved collection efficiency [1] Investment and Returns - The company’s return on invested capital (ROIC) was 13.32%, with a historical median ROIC of 15.83% since its listing [6] - The net profit margin for the previous year was 28.11%, indicating strong value addition from products or services [6] Market Position and Fund Holdings - The largest fund holding Chengyi Pharmaceutical is the "Zhaoshang Heyue Stable Pension One-Year Holding Mixed Fund (FOF) A," which has reduced its holdings [5] - The fund's current scale is 468 million yuan, with a recent net value increase of 0.33% [5]

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. reported significant growth in its 2025 semi-annual results, with a focus on marine economy and health products as key growth drivers [2] Financial Performance - The company achieved operating revenue of 417 million yuan, a year-on-year increase of 17.11% [2] - Net profit attributable to shareholders reached 112 million yuan, reflecting a 47.03% increase compared to the same period last year [2] - The net profit excluding non-recurring gains and losses was 111 million yuan, up 54.21% year-on-year [2] Business Strategy - Chengyi Pharmaceutical is committed to the dual-driven strategy of pharmaceuticals and health products, aligning with national initiatives to develop the marine economy and marine biomedicine [2] - In the pharmaceutical sector, the company focuses on a full industry chain approach, increasing R&D investment to enhance competitive advantages in clinical treatment areas such as bone and joint, cardiovascular, anti-infection, and nervous system [2] Product Development - The company prioritized key profitable products for consistency evaluation and new product development, successfully passing consistency evaluation for two specifications of sodium cytidine injection [2] - New products such as mercaptopurine tablets have been approved, and the raw material for dobutamine hydrochloride has been filed successfully [2] - As of the date of the interim report, the company has obtained a drug registration certificate for palivizumab injection [2] Market Focus - In the health product sector, the company strategically focuses on marine biomedicine and the silver economy, seizing opportunities from consumption upgrades and increased health awareness [2]

Core Insights - Chengyi Pharmaceutical (603811.SH) reported a total revenue of 417 million yuan for the first half of 2025, an increase of 60.88 million yuan compared to the same period last year, marking a 17.11% year-on-year growth [1] - The net profit attributable to shareholders reached 112 million yuan, ranking 41st among disclosed peers, with an increase of 35.96 million yuan, reflecting a 47.03% year-on-year rise [1] - The net cash inflow from operating activities was 141 million yuan, ranking 36th among peers, with an increase of 75.17 million yuan, representing a 113.74% year-on-year growth [1] Financial Ratios - The latest debt-to-asset ratio stands at 23.88%, ranking 39th among disclosed peers, a decrease of 8.92 percentage points compared to the same period last year [3] - The latest gross profit margin is 69.78%, ranking 27th among peers, with an increase of 0.81 percentage points from the previous quarter and 0.07 percentage points year-on-year [3] - The latest return on equity (ROE) is 8.76%, ranking 14th among peers, with an increase of 2.40 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.35 yuan, ranking 30th among peers, with an increase of 0.12 yuan, reflecting a 52.17% year-on-year growth [3] - The latest total asset turnover ratio is 0.24 times, ranking 38th among peers, with an increase of 0.05 times year-on-year, marking a 26.18% rise [3] - The latest inventory turnover ratio is 1.06 times, with an increase of 0.18 times year-on-year, representing a 19.96% growth [3] Shareholder Structure - The number of shareholders is 15,700, with the top ten shareholders holding 132 million shares, accounting for 40.30% of the total share capital [3] - The largest shareholder is Yan Yiyi, holding 23.58% of the shares [3]

Group 1 - The company Chengyi Pharmaceutical (SH 603811) announced on August 27 that its fifth board meeting for the third time in 2025 was held on August 25, 2025, combining in-person and communication methods [1] - The meeting reviewed the "2025 Semi-Annual Report and Summary of Zhejiang Chengyi Pharmaceutical Co., Ltd." and other documents [1] - For the year 2024, the company's revenue composition was 99.71% from the pharmaceutical manufacturing industry and 0.29% from other businesses [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices for related listed companies [1]